Widely used:Recently Viewed
Clear All$13.40
$12.19
(1,007.44%)
As on 18-Jun-2025 11:52EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$22 Mln
Revenue (TTM)
$6 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.6
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-8.8
Face value
--
Shares outstanding
1,605,760
CFO
$-222.14 Mln
EBITDA
$-223.97 Mln
Net Profit
$-303.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Finch Therapeutics Group (FNCH)
| -- | -- | -- | -- | -44.6 | -- | -- |
|
BSE Sensex*
| 4.0 | -1.1 | 8.1 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Finch Therapeutics Group (FNCH)
| -74.9 | -95.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Finch Therapeutics Group (FNCH)
|
13.4 | 22.1 | 5.7 | -14.2 | -346.0 | -76.4 | -- | 1.6 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 4.0 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.6 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.4 | |
| 25.4 | 10,055.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.3 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.5 | 1.9 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the... gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. Read more
Chief Executive Officer
Mr. Matthew P. Blischak J.D.
Chief Executive Officer
Mr. Matthew P. Blischak J.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Finch Therapeutics Group Inc (FNCH) stood at $ 50 Mln as on 30-Jun-24
The share price of Finch Therapeutics Group Inc (FNCH) is $13.40 (NASDAQ) as of 18-Jun-2025 11:52 EDT. Finch Therapeutics Group Inc (FNCH) has given a return of -44.55% in the last 3 years.
Finch Therapeutics Group Inc (FNCH) has a market capitalisation of $ 22 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Finch Therapeutics Group Inc (FNCH) is 1.55 times as on 13-Jun-2025, a 44% discount to its peers’ median range of 2.75 times.
Since, TTM earnings of Finch Therapeutics Group Inc (FNCH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Finch Therapeutics Group Inc (FNCH) and enter the required number of quantities and click on buy to purchase the shares of Finch Therapeutics Group Inc (FNCH).
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
The CEO & director of Mr. Matthew P. Blischak J.D.. is Finch Therapeutics Group Inc (FNCH), and CFO & Sr. VP is Mr. Matthew P. Blischak J.D..
There is no promoter pledging in Finch Therapeutics Group Inc (FNCH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Finch Therapeutics Group Inc. (FNCH) | Ratios |
|---|---|
|
Return on equity(%)
|
-76.36
|
|
Operating margin(%)
|
-346.02
|
|
Net Margin(%)
|
-248.98
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Finch Therapeutics Group Inc (FNCH) was $0 Mln.
